Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers

Osteoarthritis and Cartilage

Volumn 11, Issue 6, 2003, Pages 433-441

  Volpi, N ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Chondroitin sulfate; Glycosaminoglycans; Oral route; Osteoarthritis

Indexed keywords

CHONDROITIN SULFATE;

AGAR GEL ELECTROPHORESIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; DENSITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG ISOLATION; DRUG PURIFICATION; DRUG STRUCTURE; HUMAN; HUMAN EXPERIMENT; MALE; MOLECULAR WEIGHT; NORMAL HUMAN; PRIORITY JOURNAL; SHARK; VOLUNTEER;

EID: 0038344676     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1063-4584(03)00051-7     Document Type: Article

References (47)

1. Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC. Articular Cartilage and Osteoarthritis. New York: Raven Press 1991.
2. Ghosh P. Nonsteroidal anti-inflammatory drugs and chondroprotection. A review of the evidence. Drugs 1993;46:834-46.
3. Ghosh P, Holbert C, Read R, Armstrong S, Wilson D. Chondroprotection and NSAIDs. Lancet 1991; 337:1612-3.
4. Adams ME. Cartilage research and treatment of osteoarthritis. Curr Opin Rheumatol 1992;4:552-9.
5. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section. Ann Rheum Dis 1996;55:552-7.
6. Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23:1385-91.
7. Rovetta G. Galactosaminoglycuronoglycan sulfate (matrix) in therapy of tibiofibular osteoarthritis of the knee. Drugs Exp Clin Res 1991;XVII:53-7.
8. Fioravanti A, Franci A, Anselmi F, Fattorini L, Marcolongo R. Clinical efficacy and tolerance of galactosaminoglucuronoglycan sulfate in the treatment of osteoarthritis. Drugs Exp Clin Res 1991; XVII:41-4.
9. Coaccioli S, Allegra A, Pennacchi M, Mattioli C, Ponteggia F, Brunelli A, et al. Galactosaminoglucuronoglycan sulphate in the treatment of osteoarthritis: clinical efficacy and tolerance of oral and intra-articular administration. Int J Clin Pharm Res 1998;XVIII:39-50.
10. Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Osteoarthritis Cartilage Clin Rheumatol 2002; 21:231-43.
11. Uebelhart D, Thonar E, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998;6(Suppl A):39-46.
12. Bourgeois P, Chales G, Dehais J, Delcambre B, Kunz J-L, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3×400 mg/day vs placebo. Osteoarthritis Cartilage 1998;6(Suppl A):25-30.
13. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998;6(Suppl A):31-6.
14. New approaches in OA: chondroitin sulfate (CS 4&6) not just a symptomatic treatment. Litera Rheum 1999;24:3-54.
15. Imanari T, Toida T, Koshiishi I, Toyoda H. High-performance liquid chromatographic analysis of glycosaminoglycan-derived oligosaccharides. J Chromatogr A 1996;720:275-93.
16. 13C nuclear magnetic resonance identification and characterization of components of chondroitin sulfates of various origin. Carbohydr Polym 2000;41:37-45.
17. Cassaro CMF, Dietrich CP. Distribution of sulfated mucopolysaccharides in invertebrates. J Biol Chem 1977;252:2254-61.
18. Sugahara K, Tanaka Y, Yamada S, Seno N, Kitagawa H, Haslam SM, et al. Novel sulfated oligosaccharides containing 3-O-sulfated glucuronic acid from king krab cartilage chondroitin sulfate K. Unexpected degradation by chondroitinase ABC. J Biol Chem 1996; 271:26745-54.
19. Brittis PA, Canning DR, Silver J. Chondroitin sulfate as a regulator of neuronal patterning in the retina. Science 1992;255:733-6.
20. Barkalow FJ, Schwarzbauer JE. Interactions between fibronectin and chondroitin sulfate are modulated by molecular context. J Biol Chem 1994;269:3957-62.
21. Nadanaka S, Clement A, Masayama K, Faissner A, Sugahara K. Characteristic hexasaccharide sequences in octasaccharides derived from shark cartilage chondroitin sulfate D with a neurite outgrowth promoting activity. J Biol Chem 1998; 273:3296-307.
22. 1 integrin-mediated melanoma cell adhesion. J Biol Chem 1998;273:5955-62.
23. Rachmilewitz J, Tykocinski ML. Differential effects of chondroitin sulfates A and B on monocyte and B-cell activation: evidence for B-cell activation via a CD44-dependent pathway. Blood 1998;92:223-9.
24. Sakai T, Kyogashima M, Kariya Y, Urano T, Takada Y, Takada A. Importance of GlcUAβ1-3GalNAc(4s, 6s) in chondroitin sulfate E for t-PA- and u-PA-mediated Glu-plasminogen activation. Thromb Res 2000; 100:557-65.
25. McNamara PS, Barr SC, Erb HN. Hematologic, hemostatic, and biochemical effects in dogs receiving an oral chondroprotective agent for thirty days. Am J Vet Res 1996;57:1390-4.
26. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf®) and its constituents in healthy male volunteers. Osteoarthritis Cartilage 2002; 10:768-77.
27. Volpi N. 'Fast moving' and 'slow moving' heparins, dermatan sulfate and chondroitin sulfate: qualitative and quantitative analysis by agarose-gel electrophoresis. Carbohydr Res 1993;247:263-78.
28. Volpi N. Fractionation of heparin, dermatan sulfate, and chondroitin sulfate by sequential precipitation: a method to purify a single glycosaminoglycan species from a mixture. Anal Biochem 1994;218:382-91.
29. Volpi N, Bolognani L. Glycosaminoglycans and proteins: different behaviour in size exclusion-high performance liquid chromatography. J Chromatogr A 1993;630:390-6.
30. Murata K, Horiuchi Y. Molecular weight-dependent distribution of acidic glycosaminoglycans in human plasma. Clin Chim Acta 1977;75:59-69.
31. Wagner JG. Fundamentals of Clinical Pharmacokinetics. Hamilton: Drug Intelligence Publications 1975.
32. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia: Lea and Febiger 1984.
33. Rowland M, Tozer T. Clinical Pharmacokinetics. Concepts and Applications. 2nd edn. Philadelphia: Lea and Febiger 1988.
34. Volpi N. Hyaluronic acid and chondroitin sulfate unsaturated disaccharides analysis by high-performance liquid chromatography and fluorimetric detection with dansylhydrazine. Anal Biochem 2000; 277:19-24.
35. 2+-mediated oxidation of human low-density lipoproteins. Effect of normal human plasma-derived chondroitin sulfate. J Biochem Tokyo 1999; 125:297-304.
36. Uchiyama H, Kikuchi K, Ogamo A, Nagasawa K. Determination of the distribution of constituent disaccharide units within the chain near the linkage region of shark-cartilage chondroitin sulfate C. Biochim Biophys Acta 1987;926:239-48.
37. Conte A, De Bernardi M, Palmieri L, Lualdi P, Mautone G, Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittel-Forschung/Drug Res 1991;41:768-72.
38. Ronca G, Conte A. Metabolic fate of partially depolymerized shark chondroitin sulfate in man. Int J Clin Pharm Res 1993;XIII(Suppl):27-34.
39. Conte A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittel-Forschung/Drug Res 1995;45:918-25.
40. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991; 71:481-539.
41. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989;9:21-32.
42. Pescador R, Diamantini G, Mantovani M, Malandrino S, Riva A, Casu B, et al. Absorption by the rat intestinal tract of fluorescein-labelled pig duodenal glycosaminoglycans. Arzneimittelforschung 1980; 30:1893-6.
43. Larsen AK, Lund DP, Langer R, Folkman J. Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Natl Acad Sci USA 1986;83:2964-8.
44. Palmieri L, Conte A, Giovannini L, Lualdi P, Ronca G. Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneimittelforschung 1990; 40:319-23.
45. Dawes J, Hodson BA, Pepper DS. The absorption, clearance and metabolic fate of dermatan sulphate administered to man-studies using a radioiodinated derivative. Thromb Haemost 1989;62:945-9.
46. Crepaldi G, Rossi A, Coscetti G, Abbruzzese E, Calveri U, Calabrò A. Sulodexide oral administration influences blood viscosity and fibrinolysis. Drugs Exp Clin Res 1992;18:189-95.
47. Dawes J, McLaren M, Forbes C, Belch JJF, Lane DA, Bray B, et al. The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers. Br J Clin Pharm 1991;32:361-6.